Valeant Pharma jumps AH as ValueAct adds 3M shares to stake

Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company's stock valued at $648,000 after buying an additional 360 shares during the period. The stock has lost -76.86% in the past month, -81.62% in the previous three months, and -80.10% on an YTD basis. Stock has got OUTPERFORM rating from 3 analysts of Thomson Reuters, 18 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating.

A quick note on Valeant Pharmaceutical short sellers from Wall Street analytics firm, S3 Partners - something to give a little context to hedge fund billionaire Bill Ackman's exit from the company. The current consensus recommendation provided by covering analysts is 3.00.

For the Current Quarter, the growth estimate for Valeant Pharmaceuticals International, Inc.is -28.3%, while for the Next Quarter the stock growth estimate is -32.1%.

"Last week, priced a $3.25 billion bond refinancing and covenant waiver package which extends maturities and reduces the company's exposure to floating interest rates". The shares were sold at an average price of $11.00, for a total transaction of $199,258,752.00. The Insider Ownership of the company now is 2.3 percent, and Institutional Ownership is 66.8 percent.

18 analysts projected Price Targets for Valeant Pharmaceuticals International, Inc.

The fact of the matter is Pershing Square decision only came after a substantial year-long commitment to help Valeant sell key assets, establish a new management team and overhaul of the company's board. (NYSE:VRX) has a market capitalization of 3.83 Billion.

The High Revenue estimate is predicted as 2.24 Billion, while the Low Revenue Estimate prediction stands at 2.06 Billion. During the same quarter a year ago, the company posted $1.55 EPS. Kistler Tiffany Companies LLC boosted its position in Valeant Pharmaceuticals Intl by 95.5% in the third quarter.

Bill Ackman may have sold his stake in Valeant Pharmaceuticals but he can't kick the habit as lawsuits continue. The Company's shares are trading -72.85% below their 50-day moving average and -93.67% below their 200-day moving average.

Several institutional investors have recently bought and sold shares of the company. Advisor Group Inc. increased its position in Valeant Pharmaceuticals Intl by 6.3% in the third quarter. Rock Springs Capital Management LP now owns 68,600 shares of the specialty pharmaceutical company's stock worth $1,684,000 after buying an additional 2,500 shares during the last quarter.

The analysts offering Earnings Estimates for the company were believing that Valeant Pharmaceuticals International, Inc. Private Advisor Group LLC now owns 11,765 shares of the specialty pharmaceutical company's stock worth $180,000 after buying an additional 2,213 shares during the last quarter. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

  • Todd Kelly